2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Lymphoma, Follicular
1
Dementia
1
Alzheimer Disease
1
Interventions
XENP 1595
2
Electroencephalography
2
mazdutide
1
enzalutamide
1
amlodipine, atorvastatin drug combination
1
UE2343
1
Tomography, X-Ray Computed
1
Tomography, Emission-Computed
1
Tablets
1
Standard of Care
1
Referral and Consultation
1
Prednisone
1
Positron-Emission Tomography
1
Methotrexate
1
Methods
1
Magnetic Resonance Imaging
1
Lysine Acetyltransferase 5
1
Hormones
1
Gonadotropin-Releasing Hormone
1
Exercise
1
Ethanol
1
Drug Delivery Systems
1
Dignity Therapy
1
Decision Support Techniques
1
Atorvastatin
1
Aging
1
Activities of Daily Living
1
Accidental Falls
1
Abiraterone Acetate
1
7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Dementia
×
UE2343
×
Clear all
NCT06125951
2026-04-23
XanaMIA
Actinogen Medical
Phase 2/3
Active not recruiting
247 enrolled